236 related articles for article (PubMed ID: 16434487)
21. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
22. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
Nah EH; Kim SY; Cho S; Kim S; Cho HI
BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
[TBL] [Abstract][Full Text] [Related]
23. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease.
Coats CJ; Parisi V; Ramos M; Janagarajan K; O'Mahony C; Dawnay A; Lachmann RH; Murphy E; Mehta A; Hughes D; Elliott PM
Am J Cardiol; 2013 Jan; 111(1):111-7. PubMed ID: 23040658
[TBL] [Abstract][Full Text] [Related]
24. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
25. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.
Vickery S; Price CP; John RI; Abbas NA; Webb MC; Kempson ME; Lamb EJ
Am J Kidney Dis; 2005 Oct; 46(4):610-20. PubMed ID: 16183415
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
27. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
28. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.
Kristen AV; Biener M; Hegenbart U; Hardt S; Schnabel PA; Röcken C; Schonland SO; Katus HA; Giannitsis E
Int J Cardiol; 2014 Oct; 176(3):1113-5. PubMed ID: 25115253
[No Abstract] [Full Text] [Related]
30. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
31. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of serial serum N-terminal prohormone brain natriuretic peptide levels in the prediction of outcome in children with dilated cardiomyopathy.
Kim G; Lee OJ; Kang IS; Song J; Huh J
Am J Cardiol; 2013 Nov; 112(9):1455-60. PubMed ID: 24035042
[TBL] [Abstract][Full Text] [Related]
34. Relation of N-Terminal Pro-B-Type Natriuretic Peptide and Left Ventricular Diastolic Function to Exercise Tolerance in Patients With Significant Valvular Heart Disease and Normal Left Ventricular Systolic Function.
Hwang JW; Park SJ; Cho EJ; Kim EK; Lee GY; Chang SA; Choi JO; Lee SC; Park SW
Am J Cardiol; 2017 Jun; 119(11):1846-1853. PubMed ID: 28391990
[TBL] [Abstract][Full Text] [Related]
35. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
[TBL] [Abstract][Full Text] [Related]
36. NT-proBNP in monitoring treatment of patients with congestive heart failure.
Al-Meslmani BM; Fahoum SK; Shamia MG
Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
[TBL] [Abstract][Full Text] [Related]
37. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease.
Hess G; Runkel S; Zdunek D; Hitzler WE
Clin Lab; 2005; 51(3-4):167-72. PubMed ID: 15819172
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.
D'Amato R; Tomberli B; Castelli G; Spoladore R; Girolami F; Fornaro A; Caldini A; Torricelli F; Camici P; Gensini GF; Cecchi F; Olivotto I
Am J Cardiol; 2013 Oct; 112(8):1190-6. PubMed ID: 23871673
[TBL] [Abstract][Full Text] [Related]
39. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
[TBL] [Abstract][Full Text] [Related]
40. Does N-terminal Pro-brain Type Natriuretic Peptide Predict Cardiac Complications After Hip Fracture Surgery?
Ushirozako H; Ohishi T; Fujita T; Suzuki D; Yamamoto K; Banno T; Takase H; Matsuyama Y
Clin Orthop Relat Res; 2017 Jun; 475(6):1730-1736. PubMed ID: 28101755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
